Trends That Advanced CRISPR Therapies in 2021
Jan. 19, 2022
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Locus Biosciences
Main focus: New treatments against bacterial infections
Company stage: Clinical
Diseases: Urinary tract infection, other infections
Genome editing tool: CRISPR-Cas3
Funding stage: Private
Location: North Carolina, USA
Website: https://www.locus-bio.com/
Partners: Janssen Pharma
Locus Biosciences is a clinical-stage gene-editing company focused on treating bacterial infectious diseases. The company uses its next generation sequencing-based platform to rapidly identify new bacterial targets and phages. Locus uses CRISPR-Cas3 crPhages as the base of their therapies. The phages are designed using machine learning in order to optimise effectiveness against new bacterial targets.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
